内分泌治疗与老年早期乳腺癌女性认知功能下降的关联:前瞻性CLIMB研究结果
前瞻性CLIMB研究纳入273例≥70岁荷兰I-III期乳腺癌女性,在内分泌治疗前及治疗后9、15、27个月行MMSE评估。无论是否接受内分泌治疗,认知功能均未下降至有临床意义的差异;治疗前已有认知损害者MMSE评分略有改善。高龄、低教育水平和活动能力受损与MMSE评分下降独立相关,但下降无临床意义。
要点
- 老年早期乳腺癌女性启动治疗后两年内认知功能未下降,与是否接受内分泌治疗无关。
- 治疗前存在认知损害者MMSE评分随时间略有改善,全体队列和内分泌治疗组均见显著交互项。
- 高龄、低教育水平、活动能力受损与MMSE评分下降独立相关,但下降无临床意义。
核心结论
- 老年早期乳腺癌女性启动治疗后两年内认知功能未下降,与是否接受内分泌治疗无关。
- 作者认为对认知下降的恐惧不足以作为老年女性乳腺癌治疗降阶梯的依据。
研究设计与样本
- 前瞻性观察性CLIMB研究,纳入273例≥70岁荷兰I-III期乳腺癌女性,平均年龄76岁(标准差5),48%接受内分泌治疗。
- 在内分泌治疗开始前及治疗后9、15、27个月进行MMSE评估,采用线性混合模型分析认知下降的预测因素。
主要发现
- 基线平均MMSE评分为28.2(标准差1.9)。
- 无论是否接受内分泌治疗,认知功能均未下降至有临床意义的差异。
- 治疗前存在认知损害的女性MMSE评分随时间略有改善(显著交互项),见于全体队列和接受内分泌治疗者。
- 高龄、低教育水平和活动能力受损与MMSE评分随时间下降独立相关,但下降无临床意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Studies investigating the long-term effects of breast cancer treatment on cognition in older women with breast cancer are lacking, even though preserving cognition is highly valued by the older population. Specifically, concerns have been raised regarding the detrimental effects of endocrine therapy (ET) on cognition. Therefore, we investigated cognitive functioning over time and predictors for cognitive decline in older women treated for early breast cancer. METHODS: We prospectively enrolled Dutch women aged ≥70 years with stage I-III breast cancer in the observational CLIMB study. The Mini-Mental State Examination (MMSE) was performed before ET initiation and after 9, 15 and 27 months. Longitudinal MMSE scores were analysed and stratified for ET. Linear mixed models were used to identify possible predictors of cognitive decline. RESULTS: Among the 273 participants, the mean age was 76 years (standard deviation 5), and 48% received ET. The mean baseline MMSE score was 28.2 (standard deviation 1.9). Cognition did not decline to clinically meaningful differences, irrespective of ET. MMSE scores of women with pre-treatment cognitive impairments slightly improved over time (significant interaction terms) in the entire cohort and in women receiving ET. High age, low educational level and impaired mobility were independently associated with declining MMSE scores over time, although the declines were not clinically meaningful. CONCLUSION: Cognition of older women with early breast cancer did not decline in the first two years after treatment initiation, irrespective of ET. Our findings suggest that the fear of declining cognition does not justify the de-escalation of breast cancer treatment in older women.
引用
- Baltussen JC, Derks MGM, Lemij AA, et al. Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study. Eur J Cancer. 2023. PMID: 36933518. doi:10.1016/j.ejca.2023.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。